Results 71 to 80 of about 20,646 (210)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

Breast Cancer Research, 2020
Background The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer.
Swaathi Jayaraman, Xiaonan Hou, Mary J. Kuffel, Vera J. Suman, Tanya L. Hoskin, Kathryn E. Reinicke, David G. Monroe, Krishna R. Kalari, Xiaojia Tang, Megan A. Zeldenrust, Jingfei Cheng, Elizabeth S. Bruinsma, Sarah A. Buhrow, Renee M. McGovern, Stephanie L. Safgren, Chad A. Walden, Jodi M. Carter, Joel M. Reid, James N. Ingle, Matthew M. Ames, John R. Hawse, Matthew P. Goetz   +21 more
doaj   +1 more source

Cervical Metastasis From Primary Breast Carcinoma: A Case Report and Review of Extragenital Tumors Involving the Uterine Cervix

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Cervical metastases from breast carcinoma should be considered in the differential diagnosis of uterine lesions in patients with prior breast cancer. Re‐biopsy is essential to detect receptor discordance (ER/PR up to 29%) and guide therapy. GCDFP‐15, mammaglobin, and GATA3 confirm mammary origin.
Mario Assenza, Adele Zappalà, Armando Nallbani, Jacopo Wabersich   +3 more
wiley   +1 more source

A prospective double-blinded, randomized, placebo-controlled trial on the use of letrozole pretreatment with misoprostol for second-trimester medical abortion

, 2011
Background: The aim of this randomized trial was to evaluate the abortion rate of combined regimen of letrozole and misoprostol in second-trimester abortion.
Ho, PC, Lee, VCY, Tang, OS, Ng, EHY, Yeung, WSB   +4 more
core   +1 more source

Hormonal, follicular and endometrial dynamics in letrozole-treated versus natural cycles in patients undergoing controlled ovarian stimulation

Reproductive Biology and Endocrinology, 2011
The objective of this study was to compare letrozole-stimulated cycles to natural cycles in 208 patients undergoing intrauterine insemination (IUI) between July of 2004 and January of 2007. Group I (n = 47) received cycle monitoring only (natural group),
Brunengraber Lisa N, Hussein Mostafa, Mousa Noha, Abdelaleem Mahmoud A, Bedaiwy Mohamed A, Casper Robert F   +5 more
doaj   +1 more source

Optimal model‐based design of experiments for parameter precision: Supercritical extraction case

The Canadian Journal of Chemical Engineering, Volume 104, Issue 7, Page 3775-3795, July 2026.
Abstract This study investigates the process of chamomile oil extraction from flowers. A parameter‐distributed model consisting of a set of partial differential equations is used to describe the governing mass transfer phenomena in a cylindrical packed bed with solid chamomile particles under supercritical conditions using carbon dioxide as a solvent ...
Oliwer Sliczniuk, Pekka Oinas
wiley   +1 more source

Palbociclib and Letrozole in Advanced Breast Cancer

, 2016
BACKGROUND A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor ...
Lu, Dongrui R., Gelmon, Karen, Jones, Stephen, Randolph, Sophia, Rugo, Hope S., Slamon, Dennis J., Finn, Richard S., Harbeck, Nadia, Gauthier, Eric, Moulder, Stacy, Martin, Miguel, Dieras, Veronique, Lipatov, Oleg N., Im, Seock-Ah, Walshe, Janice M.   +14 more
core   +1 more source

Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07) [PDF]

, 2012
BACKGROUND The risk of osteoporosis and fracture influences the selection of adjuvant endocrine therapy. We analyzed bone mineral density (BMD) in Swiss patients of the Breast International Group (BIG) 1-98 trial [treatment arms: A, tamoxifen (T) for ...
O. Pagani, K. Zaman, M. Simcock, Lüthi, J, Giobbie-Hurder, A, C. Genton, B. Thürlimann, J. Huober, Pagani, O, A. Schönenberger, Berthod, G, Huober, J, Genton, C, Brauchli, P, Zaman, K, Schönenberger, A, S. Aebi, Thürlimann, B, Simcock, M, Aebi, S, P. Brauchli, J. Lüthi, A. Giobbie-Hurder, G. Berthod   +23 more
core   +1 more source

Letrozole Potentiates Mitochondrial and Dendritic Spine Impairments Induced by β Amyloid

Journal of Aging Research, 2013
Reduced estrogens, either through aging or postsurgery breast cancer treatment with the oral nonsteroidal aromatase inhibitor letrozole, are linked with declined cognitive abilities.
P. K.-Y. Chang, S. Boridy, R. A. McKinney, D. Maysinger   +3 more
doaj   +1 more source

GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells

BMC Cancer, 2011
Background Aromatase inhibitors (AI) that inhibit breast cancer cell growth by blocking estrogen synthesis have become the treatment of choice for post-menopausal women with estrogen receptor positive (ER+) breast cancer.
Sabnis Gauri, Brodie Angela, Abrhale Tesfom, Macedo Luciana, Tian Changsheng, Yue Binbin, Serrero Ginette   +6 more
doaj   +1 more source

Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis

Frontiers in Oncology, 2020
Background: The co-administration of letrozole during controlled ovarian stimulation (COS) with gonadotropins is used to limit the potentially harmful effects of a supra-physiological rise in estrogen levels on hormone-sensitive cancers.
Benedetta Bonardi, Benedetta Bonardi, Claudia Massarotti, Marco Bruzzone, Oranite Goldrat, Giorgia Mangili, Paola Anserini, Stefano Spinaci, Luca Arecco, Luca Arecco, Lucia Del Mastro, Lucia Del Mastro, Marcello Ceppi, Isabelle Demeestere, Isabelle Demeestere, Matteo Lambertini, Matteo Lambertini   +16 more
doaj   +1 more source